Follow the numbers: could Pfizer bid for GSK?
This article was originally published in Scrip
Executive Summary
If a recent poll of Biospace readers is anything to go by, Pfizer is on the verge of making a bid for GlaxoSmithKline – and it could be worth more than $120bn.